紫杉醇联合顺铂治疗晚期非小细胞肺癌临床观察  

Clinical observation on paclitaxel and cisplatin in the treatment of advanced non-small cell lung cancer

作　　者：王延红[1] 卢雨霖[1] 李若英[1] 

机构地区：[1]潮州市中心医院,广东潮州521000

出　　处：《基层医学论坛》2006年第2期110-111,共2页The Medical Forum

摘　　要：目的评价TP方案治疗晚期NSCLC近期疗效和毒副反应。方法TAX135mg/m2、d1,DDP75mg/m2,分5天应用,21天为1疗程。结果可评价疗效者40例,无CR病例,PR37.5%(15/40),SD47.5%(19/40),PD15.0%(6/40),临床症状改善率72.5%(29/40)。毒副作用主要为血液毒性95.0%(38/40)和恶心呕吐52.5%(21/40)。结论TP方案对晚期NSCLC有较好疗效,且不良反应可以耐受。Objective To evaluate the short-term efficacy and toxicity of TP regimen in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods The patients received TAX 135mg/m^2 on day 1, and DDP 75mg/m^2 for five days. The regimen was repeated every 21 days as a course. Results In 40 evaluable patients, there were no CR ones, PR37.5% （15/40）, SD47.5%（19/40）, PD15.0% （6/40）. the improvable rate of clinical signs was 72.5% （29/40）, the main to：deities were hematological toxicity 95.0% （38/40） ,and nausea/vomiting 52.5%（21/40）.Conlusion TP schedule has effective for advanced NSCLC and well-tolerated side effects.

关 键 词：紫杉醇顺铂 非小细胞肺癌 治疗 不良反应 

分 类 号：R734.2[医药卫生—肿瘤] R521[医药卫生—临床医学]